Current indications for CDK 4/6 inhibitors (plus antiestrogen), biomarkers
26 Oct 2016
Current indications for CDK 4/6 inhibitors (plus antiestrogen), biomarkers
Biomarkers of sensitivity and resistance
Editor's ESMO 2016 roundup
Comment: Ribociclib for breast cancer
Cancer care in Wales - challenges and opportunities
Breast cancer in Wales - a success story
From cells to singing- putting people at the centre of cancer research
Towards blood based diagnostics in cancer
Maintenance in NSCLC: Q & A
Current standards of care in advanced NSCLC
Hope, hype, misinformation and clinical evidence
Photon therapy in a proton age